Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CD4+ T helper 2 cell–macrophage crosstalk induces IL-24–mediated breast cancer suppression
Bo Wang, Yun Xia, Can Zhou, Yuhan Zeng, Heehwa G. Son, Shadmehr Demehri
Bo Wang, Yun Xia, Can Zhou, Yuhan Zeng, Heehwa G. Son, Shadmehr Demehri
View: Text | PDF
Research Article Immunology Oncology

CD4+ T helper 2 cell–macrophage crosstalk induces IL-24–mediated breast cancer suppression

  • Text
  • PDF
Abstract

CD4+ T cells contribute to antitumor immunity and are implicated in the efficacy of cancer immunotherapies. In particular, CD4+ T helper 2 (Th2) cells were recently found to block spontaneous breast carcinogenesis. However, the antitumor potential of Th2 cells in targeting established breast cancer remains uncertain. Herein, we demonstrate that Th2 cells induced by the topical calcipotriol/thymic stromal lymphopoietin cytokine axis suppressed the growth of established mammary tumors in mice. Interleukin-24 (IL-24), an anticancer cytokine, was highly upregulated in macrophages infiltrating calcipotriol-treated mammary tumors. Macrophages expressed IL-24 in response to IL-4 signaling in combination with Toll-like receptor 4 (TLR4) agonists (e.g., HMGB1) in vitro. Calcipotriol treatment significantly increased HMGB1 release by tumor cells in vivo. CD4+ T cell depletion reduced HMGB1 and IL-24 expression, reversing calcipotriol’s therapeutic efficacy. Macrophage depletion and TLR4 inhibition also reduced the therapeutic efficacy of calcipotriol. Importantly, calcipotriol treatment failed to control mammary tumors lacking the IL-24 receptor on tumor cells. Collectively, our findings reveal that Th2 cell–macrophage crosstalk leads to IL-24–mediated tumor cell death, highlighting a promising therapeutic strategy to tackle breast cancer.

Authors

Bo Wang, Yun Xia, Can Zhou, Yuhan Zeng, Heehwa G. Son, Shadmehr Demehri

×

Figure 2

Calcipotriol treatment induces Il24 expression in mammary tumors.

Options: View larger image (or click on image) Download as PowerPoint
Calcipotriol treatment induces Il24 expression in mammary tumors.
(A) Vo...
(A) Volcano plot illustrating the differential gene expression between calcipotriol- and EtOH-treated PyMt tumors. Genes up- and downregulated in calcipotriol-treated tumors are highlighted in red and blue, respectively. (B) KEGG pathway analysis of RNA-Seq results, highlighting pathways enriched in calcipotriol- compared with EtOH-treated mammary tumors. (C) Heatmap of differential gene expression associated with the cytokine-cytokine receptor interaction in calcipotriol versus EtOH treatments. (D) qRT-PCR gene expression analysis for Il24 across calcipotriol- and EtOH-treated PyMt tumors (n = 8 in each group). Results are depicted as fold change relative to the EtOH group. Bar graph shows mean + SD. Mann-Whitney U test (D).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts